300 related articles for article (PubMed ID: 31276431)
21. IgG glycosylation analysis.
Huhn C; Selman MH; Ruhaak LR; Deelder AM; Wuhrer M
Proteomics; 2009 Feb; 9(4):882-913. PubMed ID: 19212958
[TBL] [Abstract][Full Text] [Related]
22. A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.
Blundell P; Pleass R
Methods Mol Biol; 2019; 1904():417-421. PubMed ID: 30539483
[TBL] [Abstract][Full Text] [Related]
23. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
24. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
25. Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
Gstöttner C; Knaupp A; Vidarsson G; Reusch D; Schlothauer T; Wuhrer M; Domínguez-Vega E
Front Immunol; 2022; 13():980291. PubMed ID: 36159782
[TBL] [Abstract][Full Text] [Related]
26. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
27. MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc
Sénard T; Gargano AFG; Falck D; de Taeye SW; Rispens T; Vidarsson G; Wuhrer M; Somsen GW; Domínguez-Vega E
Front Immunol; 2020; 11():2049. PubMed ID: 32973813
[TBL] [Abstract][Full Text] [Related]
28. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
29. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
30. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
31. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development.
Kaur H
Crit Rev Biotechnol; 2021 Mar; 41(2):300-315. PubMed ID: 33430641
[TBL] [Abstract][Full Text] [Related]
32. Functional Role of Carbohydrate Residues in Human Immunoglobulin G and Therapeutic Monoclonal Antibodies.
Dorokhov YL; Sheshukova EV; Kosobokova EN; Shindyapina AV; Kosorukov VS; Komarova TV
Biochemistry (Mosc); 2016 Aug; 81(8):835-57. PubMed ID: 27677552
[TBL] [Abstract][Full Text] [Related]
33. Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
Lopez E; Scott NE; Wines BD; Hogarth PM; Wheatley AK; Kent SJ; Chung AW
Front Immunol; 2019; 10():2415. PubMed ID: 31681303
[TBL] [Abstract][Full Text] [Related]
34. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.
Lu J; Sun PD
Immunol Rev; 2015 Nov; 268(1):192-200. PubMed ID: 26497521
[TBL] [Abstract][Full Text] [Related]
35. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
[TBL] [Abstract][Full Text] [Related]
36. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
37. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity.
Chen CL; Hsu JC; Lin CW; Wang CH; Tsai MH; Wu CY; Wong CH; Ma C
ACS Chem Biol; 2017 May; 12(5):1335-1345. PubMed ID: 28318221
[TBL] [Abstract][Full Text] [Related]
38. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
[TBL] [Abstract][Full Text] [Related]
39. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
[TBL] [Abstract][Full Text] [Related]
40. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
